We audited the marketing at Trially AI
AI-native clinical trial patient matching and enrollment platform
This page was built using the same AI infrastructure we deploy for clients.
Month-to-month. Cancel anytime.
Recent seed funding ($4.7M, Sept 2025) but minimal visible content presence suggests early-stage GTM infrastructure gaps in pharma/CRO buyer education
1,850 LinkedIn followers for a clinical trial AI solution indicates limited thought leadership positioning among sponsors, CROs, and site networks
Competitive moat is product-driven (95% accuracy, 2-6x enrollment lift) but regulatory/compliance story appears undermarketed to risk-averse pharma buyers
AI-Forward Companies Trust MarketerHire
Plaid
MasterClass
Constant Contact
Netflix
Noom
TinuitiTrially AI's Leadership
We mapped your current team to understand where MH-1 fits in.
MH-1 doesn't replace your team. It becomes your marketing team: dedicated humans + AI agents running execution at scale while you focus on product.
Here's Where You Stand
Early-stage biotech software with strong product but nascent marketing infrastructure. Significant whitespace in SEO, paid, and founder visibility.
No visible ranking for high-intent clinical trial terms. Competitors and industry guides dominate SERPs for sponsor/CRO keywords.
MH-1: SEO agent builds clinical trial outcome content (enrollment velocity, screen fail reduction), targets CRO/sponsor buyer searches.
Zero presence in LLM responses for clinical trial AI or patient matching queries. Missing high-traffic AI assistant traffic.
MH-1: AEO agent positions Trially in ChatGPT/Claude responses for trial acceleration, regulatory compliance, and patient engagement solutions.
No visible LinkedIn or search campaigns targeting sponsors, CROs, or research sites. Estimated revenue suggests pre-scaled paid strategy.
MH-1: Paid agent runs LinkedIn ABM campaigns to trial sponsors and CRO procurement teams, Google Ads for enrollment pain point keywords.
Product differentiators (73% fewer screen fails, 91% less prescreening time) exist but lack long-form narrative in industry publications.
MH-1: Content agent produces clinical trial case studies, regulatory compliance whitepapers, enrollment benchmarks for sponsor/site audiences.
13-person team suggests limited internal operations to nurture trial sponsors post-POC or expand within existing networks.
MH-1: Lifecycle agent automates sponsor nurture sequences, tracks trial pipeline health, triggers re-engagement for multi-trial sponsors.
Top Growth Opportunities
Pharma sponsors and CROs face 30-40% screen fail rates and enrollment delays costing millions. Trially's metrics address this directly but aren't reaching decision-makers.
Content and SEO agents build outcome-focused assets (ROI calculators, enrollment velocity benchmarks) for sponsor procurement workflows.
HIPAA, SOC 2, FDA 21 CFR Part 11, ISO 27001 compliance is table-stakes but rarely emphasized. Risk-averse pharma buyers need this front-and-center.
AEO and content agents surface compliance credentials in LLM responses and industry guides targeting regulated trial environments.
Sites are trial enrollment bottlenecks. Reaching site networks and physician groups could drive bottom-up adoption and reduce sponsor sales cycles.
Outbound agent maps site networks and physician groups, LinkedIn agent builds founder credibility with site operations directors.
3 Humans + 7 AI Agents
A dedicated marketing team built specifically for Trially AI. The humans handle strategy and judgment. The AI agents handle execution at scale.
Human Experts
Owns Trially AI's growth roadmap. Pipeline strategy, account expansion playbooks, board-ready reporting. Translates AI insights into revenue.
Runs paid acquisition across LinkedIn and Google. Manages creative testing, budget allocation, and pipeline attribution.
Builds thought leadership on LinkedIn. Creates long-form content targeting your ICP. Manages the content-to-pipeline engine.
AI Agents
Monitors AI citation visibility across 6 LLMs weekly. Builds content targeting category queries to increase Trially AI's presence in AI-generated answers.
Produces LinkedIn ad variants targeting your ICP. Tests headlines, visuals, and offers at 10x the speed of manual production.
Builds lifecycle sequences: onboarding, expansion triggers, champion nurture, and re-engagement for dormant accounts.
Founder thought leadership. Builds the narrative that drives enterprise inbound from senior decision-makers.
Tracks competitors. Monitors positioning changes, ad spend, content strategy. Informs your counter-positioning.
Attribution by channel, pipeline velocity, budget waste detection. Weekly synthesis reports with AI-generated recommendations.
Weekly market intelligence digest curated from Trially AI's industry signals. Positions you as the intelligence layer. Drives inbound pipeline from subscribers.
Active Workflows
Here's what the MH-1 system would be doing for Trially AI from week 1.
AEO: Map clinical trial AI, patient matching, enrollment acceleration queries in ChatGPT/Claude. Position Trially as compliance-first alternative to manual screening and legacy CRO processes.
LinkedIn: Marla Becker (CEO Advisor, life sciences/healthtech expert) publishes on trial enrollment bottlenecks, AI-driven site efficiency, and regulatory-first product design for sponsor and CRO audiences.
Paid: LinkedIn ABM campaigns target trial sponsor teams (clinical operations, regulatory) with enrollment velocity case studies. Google Ads on 'clinical trial patient screening,' 'enrollment delays,' 'screen fail rate reduction.'
Lifecycle: Automate sponsor nurture post-POC with trial outcome reports, multi-trial expansion playbooks, and site network health dashboards. Re-engage sponsors 90 days pre-next-trial-launch.
Competitive watch: Monitor CRO announcements, trial sponsor technology partnerships, and industry enrollment benchmarks. Alert on emerging competitors in AI-native trial platforms.
Pipeline intelligence: Map sponsor trial calendars, CRO partnerships, and site network adoption. Identify high-velocity sponsor targets and optimal trial entry points.
Traditional Marketing vs. MH-1
Traditional Approach
MH-1 System
Audit. Sprint. Optimize.
3 phases. Real output every 2 weeks. You see results, not decks.
AI Audit + Growth Roadmap
Full diagnostic of Trially AI's marketing infrastructure: SEO, AEO visibility, paid, content, lifecycle. Prioritized roadmap tied to pipeline metrics. Delivered in 7 days.
Sprint-Based Execution
2-week sprint cycles. Real campaigns, not presentations. Each sprint ships measurable output across your priority channels.
Compounding Intelligence
AI agents monitor your channels 24/7. They catch budget waste, detect creative fatigue, track AI citation changes, and run A/B experiments autonomously. Week 12 is measurably better than week 1.
AI Marketing Operating System
3 elite humans + AI agents operating your growth system
Output multiplier: ~10x output at a fraction of the cost. The system gets smarter every week.
Month-to-month. Cancel anytime.
Common Questions
How does MH-1 differ from a marketing agency?
MH-1 pairs 3 elite human marketers with 7 AI agents. The humans handle strategy, creative direction, and judgment calls. The AI agents handle execution at scale: generating ad variants, monitoring competitors, building email sequences, tracking citations across LLMs, running A/B experiments autonomously. You get the quality of a senior marketing team with the output volume of a 15-person department.
What kind of results can we expect in the first 90 days?
Days 1-30: SEO audit of sponsor/CRO buyer keywords, AEO competitive mapping in LLM responses, LinkedIn audit for Marla's founder positioning. Days 31-60: Launch AEO content and SEO articles on enrollment ROI and compliance. Start LinkedIn content cadence and LinkedIn ABM to trial sponsors. Days 61-90: Measure early organic and AEO traffic, launch first paid campaigns on high-intent keywords, refine lifecycle automation for sponsor nurture.
How do LLMs currently answer clinical trial patient matching questions.
Today, ChatGPT and Claude default to generic answers about trial registries and manual outreach. Trially's AEO strategy inserts specific, sourced answers about AI-native matching, 95% accuracy rates, and HIPAA-compliant screening. When sponsors or CROs ask AI assistants about enrollment bottlenecks, they see Trially as the proven solution.
Can we cancel anytime?
Yes. MH-1 is month-to-month with no long-term contracts. We earn your business every sprint. That said, compounding effects kick in around month 3 as the AI agents accumulate data and the system learns what works for Trially AI specifically.
How is this page personalized for Trially AI?
This page was researched, audited, and generated using the same AI infrastructure we deploy for clients. The channel scores, team mapping, growth opportunities, and recommended agents are all based on real analysis of Trially AI's current marketing. This is a live demo of MH-1's capabilities.
Turn clinical trial enrollment data into competitive advantage
The system gets smarter every cycle. Let's talk about building it for Trially AI.
Book a Strategy CallMonth-to-month. Cancel anytime.